Carl Zeiss Meditec AGMEX:AFXN 68 Days Payable is 75.39 as of Dec. 2025, which is 16% above its 10-year median of 64.75. GuruFocus rates MEX:AFXN with a GF Score™ of 68/100 and a GF Value™ of MXN8,900.18. The stock has 4 warning signs investors should review. Among 795 Medical Devices & Instruments companies, Carl Zeiss Meditec AG ranks worse than 53.08% on this metric.
The historical rank and industry rank for Carl Zeiss Meditec AG's Days Payable or its related term are showing as below:
MEX:AFXN'
s Days Payable Range Over the Past 10 Years
Min: 54.82 Med: 64.75 Max: 88.61
Current: 65.41
During the past 13 years, Carl Zeiss Meditec AG's highest Days Payable was 88.61. The lowest was 54.82. And the median was 64.75.
MEX:AFXN's Days Payable is ranked worse than 53.08% of 795
companies
in the Medical Devices & Instruments industry
Industry Median: 67.87
vs MEX:AFXN: 65.41
Carl Zeiss Meditec AG Days Payable Historical Data
* Premium members only.
The historical data trend for Carl Zeiss Meditec AG's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:AFXN vs ISRG, BDX, MDLN: Days Payable Comparison
For the Medical Instruments & Supplies subindustry, Carl Zeiss Meditec AG's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Carl Zeiss Meditec AG Days Payable vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Carl Zeiss Meditec AG's Days Payable distribution charts can be found below:
* The bar in red indicates where Carl Zeiss Meditec AG's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Carl Zeiss Meditec AG's Days Payable for the fiscal year that ended in Sep. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Carl Zeiss Meditec AG (MEX:AFXN) has a Days Payable of 75.39 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Carl Zeiss Meditec AG and its competitors. This is 16% above median its historical median of 64.75. Over the past decade, Carl Zeiss Meditec AG's Days Payable has ranged from 54.82 to 88.61. According to the industry distribution chart, Carl Zeiss Meditec AG ranks #422 out of 795 companies in the Medical Devices & Instruments industry, placing it in the top 53.1%.
Is Carl Zeiss Meditec AG's Days Payable too high?
Carl Zeiss Meditec AG's current Days Payable of 75.39 is 16% above median its 10-year median of 64.75. Over the past 10 years, this metric has ranged from a low of 54.82 to a high of 88.61. The Medical Devices & Instruments industry median Days Payable is 67.87. Carl Zeiss Meditec AG's value of 75.39 is 11.1% above this industry median. Based on the distribution chart, Carl Zeiss Meditec AG ranks #422 out of 795 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Carl Zeiss Meditec AG has a GF Score™ of 68/100, reflecting its overall financial health beyond just this single metric.
How does Carl Zeiss Meditec AG's Days Payable compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Carl Zeiss Meditec AG ranks #422 out of 795 companies for Days Payable. This places Carl Zeiss Meditec AG in the lower half of its industry. The industry median Days Payable is 67.87. Carl Zeiss Meditec AG's value of 75.39 is 11.1% above this benchmark. Historically, Carl Zeiss Meditec AG's own Days Payable has ranged from 54.82 to 88.61 over the past decade. While the company's 10-year median is 64.75 vs. the industry median of 67.87, Carl Zeiss Meditec AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Devices & Instruments company?
The median Days Payable among Medical Devices & Instruments companies is 67.87, based on 795 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Carl Zeiss Meditec AG's current Days Payable of 75.39 is 11.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Carl Zeiss Meditec AG and its competitors. For the Medical Devices & Instruments industry, the median Days Payable is 67.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Carl Zeiss Meditec AG's current Days Payable is 75.39, which is 16% above median its own 10-year median of 64.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Carl Zeiss Meditec AG stock overvalued right now?
Carl Zeiss Meditec AG (MEX:AFXN) has a current Days Payable of 75.39. The stock's GF Value™ is MXN8,900.18, compared to a current price of MXN3,258.20 — trading 63.4% below its estimated fair value. The current Days Payable is 75.39, which is 16% above median its 10-year median of 64.75 and 11.1% above the Medical Devices & Instruments industry median of 67.87. Carl Zeiss Meditec AG's overall GF Score™ is 68/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Carl Zeiss Meditec AG (MEX:AFXN), the current Days Payable is 75.39 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Carl Zeiss Meditec AG (MEX:AFXN) Overvalued in 2026?
Based on GuruFocus' analysis, Carl Zeiss Meditec AG stock appears to be undervalued.
The current stock price of MXN3,258.20 is trading 63.4% below its estimated GF Value™ of MXN8,900.18.
Key valuation signals for MEX:AFXN:
Days Payable: 75.39 (16% above median its 10-year median of 64.75)
GF Value™: MXN8,900.18 vs. price of MXN3,258.20 (63.4% below fair value)
Industry Position: 11.1% above the Medical Devices & Instruments median (#422 of 795)
No single metric tells the full story. See the MEX:AFXN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Carl Zeiss Meditec is one of the largest visioncare technology companies in the world, and it operates in two segments: ophthalmic devices and microsurgery. OPT, which made up about 75% of sales in 2025, includes refractive lasers, surgical ophthalmic devices, equipment for ophthalmic diagnostics, as well as a portfolio of intraocular lenses and disposable medical instruments. With a low-teens share of the market, Zeiss is the second-largest player in the space. MCS is composed of implants, surgical instruments, and visualization devices used during neurosurgery, spine surgery, and otolaryngology surgery. With over 60% market share, Zeiss is the clear leader in the microsurgery space.
68GF Score
Get the complete analysis for MEX:AFXN
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:AFXN has been successfully added to your 
